M20-638: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL TRIAL OF EPCORITAMAB IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (R2) COMPARED TO RITUXIMAB AND LENALIDOMIDE (R2) ALONE IN SUBJECTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Follicular Lymphoma
  • Age: Between 18 Year(s) - 90 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. In order to participate in this study the following conditions must be met:
    2. Subject must have histologically confirmed Grade 1 to 3a FL stage II, III, or IV with no evidence of histologic transformation to an aggressive lymphoma at most recent representative tumor biopsy and CD20+ on a representative tumor biopsy based on the pathology report
    3. Subject must have R/R disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody in combination with (an)other anti-lymphoma agent(s)
    4. Subject must be able to swallow capsules and must not have any disease significantly affecting gastrointestinal (GI) function (e.g., resection of the stomach or small bowels, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction)

You may not be eligible for this study if the following are true:

    1. You will not be able to participate in this study if you have:
    2. A life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
    3. A current seizure disorder requiring therapy
    4. A current autoimmune disease requiring immunosuppressive therapy



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.